欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (9): 1068-1073.

• 综述与讲座 • 上一篇    下一篇

肝细胞癌相关因子与泛素-蛋白酶体通路关系的研究

王帅, 初亮, 胡晓薇, 姚继红   

  1. 大连医科大学药学院药理教研室, 大连116044, 辽宁
  • 收稿日期:2009-05-25 修回日期:2009-09-16 发布日期:2020-11-03
  • 作者简介:姚继红, 女, 博士, 教授, 研究方向:分子药理学。Tel:0411-86110410 E-mail: yaojihong65@hotmail.com
  • 基金资助:
    辽宁省科技厅资助项目(20061057)

Study between related factors of hepatocellular carcinoma and ubiquitin proteasome pathway

WANG Shuai, CHU Liang, HU Xiao-wei, YAO Ji-hong   

  1. Department of Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, Liaoning, China
  • Received:2009-05-25 Revised:2009-09-16 Published:2020-11-03

摘要: 肝细胞癌因为其治疗方法的局限性, 成为世界上致死率最高的恶性肿瘤疾病之一。泛素-蛋白酶体通路(ubiquitin-proteasome pathway, UPP)是调节多种细胞生物学过程的重要机制, 也是恶性肿瘤相关疾病调节异常的潜在靶点。本文就泛素-蛋白酶体通路与肝细胞癌发生相关因子[乙型肝炎病毒(HBV) 、P27 、NF-κB等] 的关系加以综述, 以寻找新的方法对肝细胞癌的发生发展加以干预。

关键词: 肝细胞癌, 泛素-蛋白酶体通路, 乙型肝炎病毒, P27, 核因子-κB

Abstract: Hepatocellular carcinoma is one of the largest causes of cancer-related deaths worldwide for which there are very limited effective treatment options. The ubiquitin-proteasome pathway (UPP) has rapidly become acknowledged as both critical mechanism for cellular biological function and a latent target of regulation of cancer- related disease. This review focus on the role of ubiquitin-proteasome pathway in hepatocellular carcinoma and its correlation factors (HBV 、P27 、 NF-κB, et al), in order to find novel therapeutic interventions against the genesis and development of hepatocellular carcinoma.

Key words: hepatocellular carcinoma, ubiquitinproteasome pathway (UPP), HBV, P27, NF-κB

中图分类号: